TrxR1 inhibition sensitizes hepatocellular carcinoma to Motesanib via an autophagy-ROS-JNK/ER stress axis
Shengwei Du, Peisen Zheng, Wen Li, Guorong Chen, Hanbin Chen · 2026
Read TrxR1 inhibition sensitizes hepatocellular carcinoma to Motesanib via an autophagy-ROS-JNK/ER stress axis by Shengwei Du, Peisen Zheng, Wen Li, Guorong Chen, Hanbin Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13563942.txt.
Description
Shengwei Du and colleagues test, in a 2026 laboratory study, whether blocking an enzyme called TrxR1 makes liver cancer cells more sensitive to the drug motesanib. They paired motesanib with auranofin, a drug that inhibits that enzyme, across several experimental models of hepatocellular carcinoma.
The pair killed cancer cells far more strongly together than either approach suggested alone. Blocking TrxR1 let harmful oxygen molecules build up through a self-digestion process in the cells, triggering stress responses that damaged DNA and slowed growth. Removing a key self-digestion gene reduced that damage, supporting the proposed chain. The work points drug developers toward a paired strategy for advanced liver cancer.
Catalog record
| CREATOR | Shengwei Du, Peisen Zheng, Wen Li, Guorong Chen, Hanbin Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47808 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |